166 results on '"Cleven, Arjen H. G."'
Search Results
2. Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas
3. Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours
4. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
5. Treatment of Progressive Cherubism during the Second Dental Transitional Phase with Calcitonin
6. BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
7. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation
8. Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma
9. Novel EWSR1::GFI1B gene fusion in angiofibroma of soft tissue
10. Benign and low-grade cartilaginous tumors: an update on differential diagnosis
11. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
12. Immunohistochemical Evaluation of Candidate Biomarkers for Fluorescence-Guided Surgery of Myxofibrosarcoma Using an Objective Scoring Method
13. No NFATC2 fusion in simple bone cyst of the jaw
14. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival
15. BRAFV600Eis associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
16. Genetic Stability of Driver Alterations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type and Their Relapses: A Rationale for the Use of Molecular-Based Methods for More Effective Disease Monitoring
17. Current Pathologic Scoring Systems for Metal-on-metal THA Revisions are not Reproducible
18. Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging
19. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
20. BRAFV600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
21. ARTISAN PCR: rapid identification of full‐length immunoglobulin rearrangements without primer binding bias
22. Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing
23. The Influence of Personalised Sarcoma Care (PERSARC) Prediction Modelling on Clinical Decision Making in a Multidisciplinary Setting
24. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine
25. DOG1 expression in giant-cell-containing bone tumours
26. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype
27. NTRK fusions are extremely rare in bone tumours
28. Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing.
29. B‐cell lymphoblastic lymphoma with cutaneous involvement and aKMT2Agene rearrangement
30. Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis
31. Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma
32. Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis
33. High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites
34. IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas
35. Apparent Lack of BRAF V600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis.
36. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma
37. Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies
38. IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas
39. Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging
40. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
41. High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas
42. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2fusions and common ALK upregulation
43. B‐cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
44. No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone
45. ARTISAN PCR: rapid identification of full‐length immunoglobulin rearrangements without primer binding bias
46. DOG1 expression in giant-cell-containing bone tumours
47. CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer
48. High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas.
49. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine
50. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.